Secondary Logo

Journal Logo

Correspondence

Low raltegravir transfer into the breastmilk of a woman living with HIV

Feiterna-Sperling, Corneliaa; Bukkems, Vera E.b; Teulen, Marga J.A.b; Colbers, Angela P.b; on behalf of the PANNA network

Author Information
doi: 10.1097/QAD.0000000000002624
  • Open

A raltegravir-based regimen is among the preferred for pregnant women living with HIV [1,2], making raltegravir a widely used antiretroviral drug in new mothers in high-income countries. European [1] and US [2] guidelines recommend against breastfeeding because of the potential risk of mother-to-child transmission (MTCT). Nevertheless, an increasing number of HIV-infected mothers is breastfeeding their newborns [3], and it is an ongoing debate if the cultural, psychological and social importance of breastfeeding outweighs the MTCT risk in some circumstances [4–8]. Adequate antiretroviral therapy is of particular importance in these women to prevent transmission, but it is widely unknown, which antiretroviral drugs (ARVs) are preferable for these women [5]. Here, we present the first case of raltegravir in a breastfeeding mother.

A 36-year-old HIV-1-infected woman received raltegravir 800 mg once daily (decreased dose because of low body weight) and emtricitabine/tenofovir disoproxil 200/245 mg once daily. Her plasma HIV-RNA has remained <20 copies/ml for more than 6 years. At 41 + 3 weeks of gestation, she delivered a healthy boy (3580 g, 55 cm, APGAR score 9 at 5 min), who received neonatal prophylaxis with oral zidovudine for 14 days [9]. Breastfeeding was chosen, with exclusive breastfeeding until 4 months of age followed by mixed feeding until the age of 9 months. A mild elevation of total bilirubin levels with normal liver function tests was observed at 14, 32, 48, and 90 days of age (6.71 [conjugated 0.61], 4.58, 5.99, and 1.42 mg/dl, respectively). Infant HIV-DNA PCR results were consistently negative up to the age of 8 months.

Maternal blood (at 4 months) and breastmilk samples (4 and 8 months postpartum) were obtained for pharmacokinetic analyses after observed maternal raltegravir intake with food to assess the breastmilk transfer and estimate infant exposure to raltegravir. A single infant blood sample was taken at 4 h after maternal dosing (assumed Tmax) to assess the infant's exposure. The plasma samples were analyzed using a validated ultra-performance liquid chromatography tandem mass spectrometry assay [lower limit of quantification (LLOQ) 0.01 mg/l] [10]. The method was adapted for analysis of breastmilk samples, which were determined relative to a breastmilk linear calibration curve (0.01–10 mg/l) resulting in circa results of the breastmilk concentration.

An AUC0–12h milk-to-plasma (M:P) ratio of 0.46 was calculated from the paired data of 4 months postpartum (noncompartmental analysis using Phoenix 63), indicating low raltegravir transfer into the breastmilk and little accumulation. A similar M:P ratio (range 0.37–0.71) was observed during the sampling interval (Fig. 1a). A similar breastmilk exposure and M : P ratio (0.55) was observed at 8 months postpartum (Fig. 1b). The unexpected delayed Tmax (12 h) at 4 months postpartum could be attributed to a migraine attack the woman suffered from during blood collection and/or the erratic absorption of raltegravir [11,12].

Fig. 1
Fig. 1:
Total raltegravir concentrations in maternal plasma, breastmilk and infant plasma at 4 and 8 months postpartum.

At 4 and 8 months postpartum, the infant's raltegravir plasma concentrations (∼45 min after last breastfeeding) were below the LLOQ (Fig. 1). At 4 months postpartum, the estimated infant dosage of the exclusively breastfed infant was 0.099 mg/kg/day, based on an average infant daily milk intake of 150 ml/kg, weight of 6.7 kg, and an average raltegravir breastmilk concentration of 0.66 mg/l (derived from AUC0–12h) [13]. This estimated daily infant dosage corresponded to 0.8% of the approved daily raltegravir dose of 12 mg/kg/day [14].

We showed for the first time that raltegravir can penetrate into breastmilk. The clinical relevance of infant exposure to different ARVs via breastmilk is discussed critically. Therapeutic antiretroviral infant exposure may protect against HIV transmission, whereas low level antiretroviral exposure can result in the development of resistance and false-negative HIV-tests in case of infection [15,16]. The relative raltegravir dose ingested by the tested infant is unlikely to be of therapeutic clinical significance as it seems to be less than 1% of the approved treatment dose and the infant exposure is beneath the protein-adjusted IC95 of 0.016 mg/l [17].

Raltegravir and bilirubin are both metabolized by UGT1A1 and compete for albumin binding sites [18]. In this case, the UGT1A1 activity of the infant was probably matured at the time of sampling, whereas low UGT1A1 activity in neonates may result in higher raltegravir concentrations [18,19]. The observed hyperbilirubinemia could, therefore, be not only attributed to the raltegravir exposure via breastmilk but also to intrauterine raltegravir exposure as reported in nonbreastfed infants after intrauterine integrase inhibitor exposure [20–22]. More longitudinal data, especially in the neonatal period, are needed to establish the applicability of raltegravir in breastfeeding HIV-infected mothers.

The study was approved by the local ethics committee (Charité-Universitätsmedizin Berlin), the mother gave written informed consent.

Acknowledgements

The authors wish to thank the patient and her family for participating in the study.

The PANNA network is supported by the European AIDS Treatment Network/European Commission/DG Research, Sixth Framework program (contract LSHP-CT-2006-037570), Gilead B.V., Bristol Myers Squibb, ViiV Healthcare, Merck Sharp & Dohme Corp, and Janssen Pharmaceutica.

Conflicts of interest

There are no conflicts of interest.

References

1. EACS. The European Guidelines for the treatment of HIV-positive adults in Europe: version 10.0 2019. Available at: https://www.eacsociety.org/files/2019_guidelines-10.0_final.pdf.
2. DHHS. Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States 2020 [updated 17-01-2020. Available from: https://files.aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf.
3. Tuthill EL, Tomori C, Van Natta M, Coleman JS. In the United States, we say, ’No breastfeeding’ but that is no longer realistic’: provider perspectives towards infant feeding among women living with HIV in the United States. J Int AIDS Soc 2019; 22:e25224.
4. Freeman-Romilly N, Nyatsanza F, Namiba A, Lyall H. Moving closer to what women want? A review of breastfeeding and women living with HIV in the UK and high-income countries. HIV Med 2020; 21:18.
5. Waitt C, Low N, Van de Perre P, Lyons F, Loutfy M, Aebi-Popp K. Does U=U for breastfeeding mothers and infants? Breastfeeding by mothers on effective treatment for HIV infection in high-income settings. Lancet HIV 2018; 5:e531e536.
6. Etowa J, MacDonald S, Hannan J, Phillips JC, Boadu NY, Babatunde S. Sociocultural factors influencing infant-feeding choices among African immigrant women living with HIV: a synthesis of the literature. J Am Assoc Nurse Pract 2018; 30:208235.
7. Johnson G, Levison J, Malek J. Should providers discuss breastfeeding with women living with HIV in high-income countries?. An Ethical Analysis Clin Infect Dis 2016; 63:13681372.
8. Kahlert C, Aebi-Popp K, Bernasconi E, Martinez de Tejada B, Nadal D, Paioni P, et al. Is breastfeeding an equipoise option in effectively treated HIV-infected mothers in a high-income setting?. Swiss Med Wkly 2018; 148:w14648.
9. DAIG. Deutsch-Österreichische Leitlinie zur HIV-Therapie in der Schwangerschaft und bei HIVexponierten Neugeborenen 2017. Available at: https://daignet.de/site-content/hiv-leitlinien/leitlinien-1/Deutsch_Osterreichische%20Leitlinie%20zur%20HIV_Therapie%20in%20der%20Schwangerschaft%20und%20bei%20HIV_exponierten%20Neugeborenen%20Stand%20Marz%202017.pdf.
10. Bollen PDJ, de Graaff-Teulen MJA, Schalkwijk S, van Erp NP, Burger DM. Development and validation of an UPLC-MS/MS bioanalytical method for simultaneous quantification of the antiretroviral drugs dolutegravir, elvitegravir, raltegravir, nevirapine and etravirine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2019; 1105:7684.
11. Tokola RA, Neuvonen PJ. Effect of migraine attacks on paracetamol absorption. Br J Clin Pharmacol 1984; 18:867871.
12. Brainard DM, Friedman EJ, Jin B, Breidinger SA, Tillan MD, Wenning LA, et al. Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics. J Clin Pharmacol 2011; 51:422427.
13. FDA. Draft Guidance: Clinical Lactation Studies: considerations for Study Design 2019. Available at: https://www.fda.gov/media/124749/download.
14. EMA. Isentress: Summary of Product Characteristics 2019.
15. Zeh C, Weidle PJ, Nafisa L, Lwamba HM, Okonji J, Anyango E, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med 2011; 8:e1000430.
16. Fogel J, Li Q, Taha TE, Hoover DR, Kumwenda NI, Mofenson LM, et al. Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. Clin Infect Dis 2011; 52:10691076.
17. Adams JL, Greener BN, Kashuba AD. Pharmacology of HIV integrase inhibitors. Curr Opin HIV AIDS 2012; 7:390400.
18. Clarke DF, Acosta EP, Cababasay M, Wang J, Chain A, Teppler H, et al. Raltegravir (RAL) in neonates: dosing, pharmacokinetics (PK), and safety in HIV-1-exposed neonates at risk of infection (IMPAACT P1110). J Acquir Immune Defic Syndr 2020; 84:7077.
19. Kawade N, Onishi S. The prenatal and postnatal development of UDP-glucuronyltransferase activity towards bilirubin and the effect of premature birth on this activity in the human liver. Biochem J 1981; 196:257260.
20. Waitt C, Orrell C, Walimbwa S, Singh Y, Kintu K, Simmons B, et al. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: a randomised trial (DolPHIN-1 study). PLoS Med 2019; 16:e1002895.
21. Schalkwijk S, Feiterna-Sperling C, Weizsacker K, Colbers A, Buhrer C, Greupink R, et al. Substantially lowered dolutegravir exposure in a treatment-experienced perinatally HIV-1-infected pregnant woman. AIDS 2016; 30:19992001.
22. Clarke DF, Acosta EP, Rizk ML, Bryson YJ, Spector SA, Mofenson LM, et al. Raltegravir pharmacokinetics in neonates following maternal dosing. J Acquir Immune Defic Syndr 2014; 67:310315.
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc.